Long Term Methotrexate Therapy Beneficial for Juvenile Localized Scleroderma PDF Print E-mail
Wednesday, 20 February 2013 00:03
Researchers in Italy evaluated 65 patients with Juvenile Localized Scleroderma (JLS; or morphea) previously enrolled in a double blind, randomized control trial and treated for the first 3 months with oral methotrexate (MTX; 15 mg/m2 weekly) and prednisone (1 mg/kg daily, maximum 50 mg). Clinical evaluation, infrared thermography and computerized skin scores were used to evaluate lesions.

Patients were defined as responders if they satisfied criteria including no new lesions, skin score rate less than 1 and a decrease in lesion temperature by at least 10% compared with baseline. Maintaining responder status after stopping treatment for at least 6 months was classified as clinical remission (CR), and response maintained while taking MTX for at least 6 months defined CR on medication (CRM).

Fifty-eight patients (mean age, 9.4 years; 72.4% female) were followed up during a mean of 40.3 months; seven were lost to follow-up. Forty-eight patients were responders at the last follow-up, while 10 patients relapsed within 24 months of MTX initiation. Responders were evaluated every 3 to 4 months during a mean of 43 months. Thirty-five responders received MTX for a mean of 27.5 months and then maintained CR for 25.6 months or longer without MTX. Thirteen other responders were in CRM. Twenty-eight patients experienced mild MTX-related side effects, including nausea and headache, but maintained treatment.

Researchers cited difficulty in comparing data to previous studies because objective measures such as infrared thermography and computerized skin score were unavailable.

“Long-term maintenance MTX treatment is beneficial for localized scleroderma (morphea) in young patients and is generally well tolerated with rare occurrence of significant adverse events,” the researchers concluded. “We recommend an initial 3 months of combined MTX-corticosteroid therapy and MTX treatment duration of at least 24 months to ensure a prolonged and sustained disease remission for the majority of the patients.”

Source: Healio Dermatology (2013), "Long-term methotrexate therapy effectively treated juvenile localized scleroderma"; Original article can be viewed here.

 
More articles :

» arGentis Expands Scientific Advisory Board

is a diversified biopharmaceutical development company located in Memphis, Tennessee. The company’s pipeline consists of mid- and late-stage platform technologies in both autoimmunity and ophthalmology. According to , the company announced...

» Predictors Of Interstitial Lung Disease In Early Systemic Sclerosis

Introduction: The objective of the present study was to examine the association of baseline demographic andclinical characteristics with sequentially obtained measurements of forced vital capacity (FVC), expressed as apercentage of the predicted...

» Scleroderma Drug In Development

According to , has partnered with , the health care investment arm of Morgan Keegan and Co. Inc., to jump-start a capital campaign to raise $12 million to $15 million. ArGentis shelved the campaign last year when the economy soured.The money will...

» Palliative Care

Palliative care (pronounced pal-lee-uh-tiv) is the medical specialty focused on improving the quality of life of people facing serious illness. Emphasis is placed on pain and symptom management, communication and coordinated care. Palliative care is...

» Treatment for Pulmonary Arterial Hypertension Cleared

has recently reported in its that the FDA has cleared Tyvaso (treprostinil) Inhalation Solution for the treatment of pulmonary arterial hypertension (PAH). Developed by United Therapeutics Corp., of Silver Spring, Md., treprostinil is indicated to...

» What Is Barrett's Esophagus?

Barrett's is a precancerous condition in which the lining of the esophagus is replaced by abnormal cells, with the esophagus being that tube which connects the throat to the stomach. The esophagus is connected to the stomach by a muscular ring...